<DOC>
	<DOC>NCT00460811</DOC>
	<brief_summary>The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.</brief_summary>
	<brief_title>Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Must not be pregnant or breastfeeding and agree to use birth control; Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinicallysignificant laboratory or physical examination findings; Meets protocoldefined criteria for IBSC, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria; Demonstrates English fluency and has access to a touchtone telephone. Recent history of mushy or watery stools; Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study; Clinicallysignificant alarm symptoms; Secondary causes of constipation or evacuation disorders; Surgery to the gastrointestinal tract; Usage of prohibited medications.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Irritable Bowel Syndrome with Constipation</keyword>
	<keyword>IBS</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>linaclotide acetate</keyword>
	<keyword>linaclotide</keyword>
	<keyword>MD-1100</keyword>
</DOC>